Clinical trial

Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)

NCT00144170

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Tipranavir (with low dose ritonavir) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Comparator protease inhibitor(CPI)/low dose ritonavir(r) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2003-02-01

PhasePHASE3

Conditions

HIV Infectionsunresolved

Interventions

Tipranavir (with low dose ritonavir)DRUG

Comparator protease inhibitor(CPI)/low dose ritonavir(r)DRUG

Sponsors & collaborators

Boehringer Ingelheimlead sponsor

Mapped research locations

ParisFrance7 MadridSpain6 LondonUnited Kingdom6 Buenos AiresArgentina6 AthensGreece6 BarcelonaSpain4 MilanItaly4 RomaItaly4 HamburgGermany3 TorinoItaly3 BerlinGermany2 ValenciaSpain2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00144170 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.